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ABSTRACT

Fu, Richard, B. S., University of South Alabama, May 2022. Applying MCI-062, a Novel
Pan-RAS Inhibitor, to Treat KRAS-Mutant Lung Cancer. Chair of Thesis Committee:
Gary Piazza, Ph.D.
RAS is a prevalent oncogene that is mutated in 27% of human cancers. Gain-offunction RAS mutations activate multiple downstream pathways, including the RASRAF-MEK-ERK and PI3K/AKT/mTOR pathways, which are critical in tumorigenesis
and cancer cell proliferation. RAS proteins such as KRAS, a member of the RAS protein
family, and their downstream effectors are attractive targets for cancer therapy since their
mutations act as frequent drivers in lung, colorectal, and pancreatic cancers. However,
RAS proteins have relatively smooth surfaces that lack traditional binding pockets,
making inhibitors specific to RAS difficult to create. Recently, a novel small molecule
pan-RAS inhibitor named MCI-062 was developed in Dr. Gary Piazza's Drug Discovery
Research Center at the Mitchell Cancer Institute. As a potential pan-RAS inhibitor, MCI062 is hypothesized to serve as a targeted therapy for RAS-mutant cancers regardless of
mutation isoform, including all types of KRAS-mutant lung cancers. The inhibitory
effects of MCI-062 were tested on the growth and proliferation of two non-small cell
lung cancer cell lines, A549 and H358, using colony formation assays. The cells were
plated onto 12-well plates, treated with varying concentrations of MCI-062, and then
digitally imaged and analyzed. A549 cells have a KRASG13D mutation, while H358 cells
have a KRASG12C mutation. The results indicate that MCI-062 effectively suppresses the
growth and proliferation of both A549 and H358 cells despite their differing mutation
isoforms, suggesting that MCI-062 successfully functions as a pan-RAS inhibitor.
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CHAPTER I
INTRODUCTION

1.1 Cancer Statistics
As the second leading cause of death in the United States (US), cancer is a major
public health issue. Each year, the American Cancer Society (ACS) reports on the most
recent facts about cancer in the US (1, 2). The cancer death rate hit its peak in 1991, with
215 out of every 100,000 people dying from cancer. Since then, the death rate from
cancer in the US has declined, as from 1991 to 2018 the cancer death rate fell by 31% (13). In regard to cancer-related mortality, lung cancer resulted in the highest mortality rate
across all types of cancer worldwide, accounting for one-quarter of all cancer-related
deaths for cancer patients (1).
Cancer is typically labeled in stages from I to IV, with IV being the most serious (1,
3, 4). Stage I cancer is a small, one-area disease that is also called early-stage cancer. In
stages II and III, tumors are characterized as larger, reaching out to nearby tissues or lymph
nodes. In stage IV, the cancer has spread to other parts of the patient’s body, which is called
an advanced or metastatic cancer (1, 3, 4). The types of treatment administered depend on
the type and the stage of cancer (4). An early-stage cancer patient may only need one
treatment, such as surgery, while an advanced-stage cancer may need a combination of
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treatments, such as surgery combined with chemotherapy and/or radiation therapy (1, 4,
5). Immunotherapy, targeted therapy, or hormone therapy are recently-developed
treatments that may be used for a special population of cancer patients (6-8).

1.2 Carcinogenesis
Carcinogenesis, also called tumorigenesis or oncogenesis, is the formation of a
cancer, when normal cells are transformed into cancer cells (1, 9). The process is
characterized by changes at the cellular, genetic, and/or epigenetic levels that drive
abnormal cell division (9). Universally recognized characteristics of cancer are unlimited
growth, evasion of immune surveillance, nonfunctional growth suppressors, sustained
angiogenesis, and the possibilities of tissue invasion and metastasis (1, 9).
Carcinogenesis is a complex and dynamic process consisting of three stages:
initiation, progression, and metastasis (9, 10). According to the clonal theory of
carcinogenesis, tumors start from a single mutated cell (11). After the initiation of cancer,
this mutated cell begins to divide and spread throughout the organ in which it manifested,
as mutated cells ignore growth inhibition and apoptotic signals. Finally, once the cancer
has grown large enough, individual tumor cells can break away from the main tumor and
enter the bloodstream or lymphatic system, and these cells eventually reach different
parts of the body and cause cancer metastasis.
Multiple studies have demonstrated that at a molecular level, carcinogenesis is
initiated by the activation of oncogenes and inhibition of tumor suppressor genes (9, 10).
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Oncogenes are regulatory factors of carcinogenesis that, once mutated, drive the growth
and proliferation of cancer cells (11-13). Chromosomal translocation, point mutations,
and gene amplification lead to oncogene activation (11). Furthermore, tumor-suppressor
genes block the growth of cancer and contribute to the normal development of cells. The
loss of function of tumor suppressor genes leads to inhibition of apoptosis, or
programmed cell death, and thus to cell immortality, which in turn promotes
carcinogenesis (11). Angiogenic factors, such as VEGF, play a key role in solid tumor
formation and development by regulating the formation of new tumor blood supply
(angiogenesis) (11). Since carcinogenesis cannot be initiated by a single mutation,
oncogene and tumor suppressor gene mutations work together synergistically to induce
carcinogenesis. Understanding these signaling pathways may provide a basis for better
anticancer approaches.

The protein products of oncogenes typically represent components of signal
transduction pathways, including growth factors, growth factors receptors, GTPases,
protein kinases, or transcription factors (12). Oncogenic activation leads to
carcinogenesis by regulating fundamental cellular processes, such as growth control,
metabolism, proliferation, and differentiation, through constitutive activation of
mitogenic signaling pathways (12). Finally, cancer is formed by uncontrolled growth of
malignant cancer cells.
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1.3 Development of Cancer Treatments
Recent cancer research has led to significant advances in therapies used to inhibit
and treat cancer cell growth (1, 3, 4, 6-8). Cancer survival has improved since the mid1970s, which partially reflects lead time bias because of changes in early diagnosis and
treatment protocols, including the discovery of targeted therapies (3, 7).
The most commonly-used treatments for cancer are surgery, chemotherapy, and
radiation therapy (1-3). Other treatment options include targeted therapy,
immunotherapy, and hormonal therapy (6, 7). In recent years, biotechnological
investigations have identified complex and unique biological features associated with
carcinogenesis (6, 7). Tumor cell profiling and immune marker analyses are used to
identify and optimize anticancer therapies in individual cancer patients (6, 7). These
targeted cancer therapies are also known as precision medicines, which are a form of
treatment that uses the individual profile of a person’s genes and proteins (14). The
rapidly expanding knowledge on the roles of genomics and the immune system in cancer
development has enabled the development of therapies targeted to specific molecular
alterations and immune suppression (14). Targeted cancer therapies differ from
standard chemotherapy and radiation therapy in several ways (15). For example, while
most traditional cytotoxic chemotherapy agents act on all rapidly-dividing cells in the
body, targeted therapies aim to act only on the specific molecular targets associated with
cancer cells (9, 14).
Certain mutant genes and proteins contribute to cancer growth and survival both
in the actual tumor cells, such as RAS genes, and in cells related to cancer growth, such as

4

the VEGF gene for blood vessel cells (15, 16, 17, 18). Doctors often use targeted therapy
in combination with chemotherapy and other treatments (4, 8). The United States Food
and Drug Administration (FDA) has approved targeted therapies for many types of
cancer (6, 7). As shown in Table 1, there are two types of targeted therapies: 1)
monoclonal antibodies, which block a specific target protein on the outside of cancer
cells and/or protein in the tumor microenvironment to directly or indirectly inhibit the
growth of cancer cells; and 2) small-molecule drugs, which act intra cellularly on the
molecule controlling cancer cells’ growth and spread (6, 7, 11).

NSCLC, non-small cell lung cancer. CRC, colorectal
cancer.
Mutant EGFR is targeted in NSCLC. EGFR overexpression
is targeted in CRC.
Adapted from (17) Duffy MJ. Int. J. Cancer. 2021;148:8–
17.
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1.4 RAS Oncogene and RAS Proteins
The RAS oncogene has been extensively studied for over three decades (12, 23,
24). The function of RAS proteins in cancer involves controlling cellular proliferation
and differentiation (18, 25). The three RAS oncogenes, HRAS, KRAS, and NRAS, were the
first to be discovered and identified and are the most frequently mutated genes in human
cancer (17, 18, 25). The RAS proteins contain a G-domain, C-terminal domain, and Cterminal CAAX box as three major domains (26). The G-domain contains the guanine
nucleotide binding site and, through interaction with a guanine nucleotide exchange
factor (GEF), is responsible for GDP-GTP exchange acting as a “molecular switch”
between the GDP-bound (inactive) and GTP-bound (active) forms. The C-terminal
domain acts as a hypervariable region that may play a role in determining the isoformspecific function of RAS proteins by sequence divergence, and the C-terminal CAAX
box is involved in a tremendous number of cellular signaling processes and regulatory
events, including cell proliferation, differentiation, and apoptosis. RAS mutations such as
G12C and G13D are single amino acid substitutions that impair the intrinsic and GAPstimulated GTP hydrolysis activities of RAS proteins, rendering them persistently GTPbound in the absence of extracellular stimuli. This persistently GTP-bound state
excessively transmits growth signals and activates the RAS-RAF-MEK-ERK and
RAS/PI3K/AKT/mTOR signaling cascades, which leads to the dysregulation of cell
growth and differentiation resulting in tumorigenesis as shown in Figure 1. (17, 18, 25,
27).
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Figure 1. Simplified scheme of Mitogen Activated Protein Kinase activation and
signaling cascades, RAS-RAF-MEK-ERK, and RAS-PI3K-AKT-mTOR
pathways. Based on upstream signaling, RAS proteins are activated by GEF, which
exchanges GDP for GTP. Active RAS then binds to and sends signals down the
RAF-MEK-ERK pathway and the PI3K/AKT/mTOR pathway, which induce cell
proliferation and survival, respectively.
Adapted from (26) Uprety D, Adjei AA. Cancer Treat Rev. 2020. 89:102070

RAS mutations are most common in the top three deadly cancers: pancreatic
cancer (95% express RAS mutations), colorectal cancer (52% express RAS mutations),
and lung cancer (31% express RAS mutations) (17, 18, 25). The development of
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therapeutic strategies to block the activity of RAS proteins has the potential to be a highly
effective method of anti-cancer treatment (23). However, the past misconception that all
RAS proteins have identical functions has led to unsuccessful attempts to develop antiRAS drugs (17, 18, 22). In addition, RAS has been deemed “undruggable” for quite some
time for three main reasons: 1) all three RAS proteins lack a readily identifiable,
accessible deep pocket, 2) RAS proteins have an unusually high affinity for their native
ligand (GTP), and 3) all three proteins are located intracellularly on the inner layer of the
cell membrane (17, 18, 22, 23). Consequently, they cannot be reached easily with high
molecular weight drugs, such as monoclonal antibodies (17). Recently, appreciation of
the fact that different RAS proteins have distinct roles has shifted the drug development
focus toward KRAS, the RAS isoform most frequently mutated in cancer patients (20, 24,
26, 28). As seen in Figure 2, the downstream non-RAS proteins, such as those of the
RAF-MEK-ERK and PI3K/AKT/mTOR pathways, have been targeted for drug therapy
in the past to varying degrees of success. These treatments hold potential for use in
combination therapies with RAS inhibitors to avoid the problem of developing drug
resistance to one drug treatment.
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ERK

Figure 2. Proteins in the RAS-RAF-MEK-ERK pathway that have been targets of
drug therapy. Drugs have been developed for targeting certain mechanisms at the
RAS/KRAS level, and other drugs target proteins downstream of RAS, such as RAF,
MEK, ERK.
Adapted from (26) Uprety D, Adjei AA. Cancer Treat Rev. 2020. 89:102070

1.5 Lung Cancer and RAS Inhibitors
Lung cancer is the leading cause of cancer-related mortality. Based on histology,
there are two main subtypes of lung cancer that have been defined: small cell lung cancer
(SCLC, 10%) and non-small cell lung cancer (NSCLC, 90%) (17, 20, 21, 23). KRAS is
mutated in 31% of NSCLC patients (20, 22). There are several missense mutations in
single amino acids in different KRAS cancers, including hotspots in codons 12, 13, and
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61. The G12C, G12D, and G13D mutations are the most common focus in recent targeted
drug development (18, 20, 21, 26). These mutations are associated with resistance to
EGFR tyrosine kinase inhibitors and to chemotherapy (25, 27, 32).
KRASG12C is particularly prevalent in NSCLC, with approximately 13% of
Americans with NSCLC expressing the KRASG12C mutation (20, 24, 26). There are about
23,000 new cases of NSCLC with KRASG12C mutation every year (24). KRASG12C is also
found in 1-3% of colorectal and pancreatic cancer patients (20, 24, 26). The most
successful approach to inhibiting RAS oncogenic kinases is KRASG12C inhibition. This is
achieved by taking advantage of the substitution of the unreactive glycine residue with
the reactive mutant cysteine residue present on mutant KRAS to covalently bind the
inhibitor to (32). KRASG12C inhibitors are designed to target a specific pocket, a recentlydiscovered allosteric binding pocket/Switch-II pocket (S-IIP) that can be used to
selectively target KRASG12C mutant cells while sparing normal cells (32). At this point in
time, three KRAS inhibitors are being studied in clinical trials: AMG 510 (Amgen),
MRTX849 (Mirati Theapeutics and Novaratis), and GDC-6036 (Roche) (32). On June 3,
2019, Amgen announced that its AMG 510 drug would be the first FDA-granted novel
small-molecule inhibitor for KRASG12C to reach the clinical stage of testing after more
than three decades of RAS research (24). AMG 510 was designed by targeting the
cysteine residue present only on the mutant KRASG12C protein, which explains why
AMG 510 does not show activity against other KRAS mutation isoforms (24, 26, 32).
The data from its phase I clinical trial demonstrated that AMG 510 leads to a disease
control rate of 90%, with partial response and stable disease in NSCLC patients when
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orally administered as a monotherapy with mild adverse effects (24, 26). On May 28,
2021, AMG 510 (sotorasib/Lumakras™, Amgen, Inc.) was formally approved for clinical
use to treat advanced NSCLC under the name of Lumakras (20). The success of AMG
510 has encouraged the RAS research community to explore more selective KRAS
inhibitors.

1.6 Study of MCI-062
From an extensive screening, Dr. Piazza’s Drug Discovery Center Lab at the
Mitchell Cancer Institute (MCI) synthesized a novel small molecule inhibitor called
MCI-062 that potently and selectively inhibits the growth of tumor cell lines harboring
constitutively activated KRAS (29). Unlike the KRASG12C inhibitors, MCI-062 is not
limited by RAS mutation type (30). As such, it promises to offer a significant advantage
as a cancer therapy due to its potential to benefit a broader base of patients. In previous
studies, Piazza and Keeton demonstrated that MCI-062 inhibits KRAS-driven pancreatic
and colorectal tumor cell growth in an isoform-independent manner by blocking GTP
loading of KRAS (32). The research project reported here focused on a preliminary
investigation of a novel small molecular pan-RAS inhibitor MCI-062 as a novel therapy
for KRAS-driven cancer patients, a population in desperate need of more effective
treatment options. Although the exact mechanisms of MCI-062 are still being studied and
outside of the scope of this project, it explored the viability of the pan-RAS inhibitor
MCI-062 for the treatment of the KRAS-mutant lung cancer cells.
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CHAPTER II
HYPOTHESIS AND AIMS

The hypothesis of this project was that treatment with pan-RAS inhibitor MCI-062
inhibits proliferation of KRAS-mutant A549 and H358 lung cancer cells. A549 and H358
are NSCLC cells that express KRASG13D and KRASG12C mutations, respectively. MCI-062
was expected to inhibit the proliferation of lung cancer cells with KRAS mutations and to
act as a more effective inhibitor of KRAS-mutant cancer growth than AMG 510 due to
MCI-062’s proposed ability to act as a pan-RAS inhibitor and inhibit all mutant isoforms
of RAS as opposed to AMG 510’s selective inhibition of KRASG12C mutations. The aims
of the project were as follows:

1. To determine whether there are optimal conditions for colony formation in the A549
and H358 cells.
2. To determine whether there is an optimal concentration of MCI-062 for inhibition of
colony formation for the A549 and H358 cells.
3. To compare whether the tumor-inhibiting effects of MCI-062 are equal to or better
than those of AMG 510 in the A549 and H358 cells.
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CHAPTER III
MATERIALS AND METHODS

3.1 Cell Lines and Inhibitors
Cell lines expressing different RAS mutants are available at:
https://www.cancer.gov/research/key-initiatives/ras/outreach/reference-reagents/celllines. Two NSCLC cell lines, H358 and A549, were used in this project.
The A549 and H358 cells lines were obtained from the American Type Culture
Collection (ATCC). MCI-062 is synthesized on-site, so it was obtained directly from the
Mitchell Cancer Institute (MCI). AMG 510 was purchased from Selleck Chemicals, LLC
(Houston, TX) for research purposes.
First, the A549 and H358 cell lines were cultured by growing them in 10 mL cell
culture dishes and passaging the cells into new dishes every 3-4 days once the cells
reached confluence. Once the materials were prepared for the colony formation assays,
the cells were plated into 12-well plates at different cell concentrations (control) or with
different dose concentrations of MCI-062 at optimal cell concentrations (in duplicate) in
a serial dilution for use in a colony formation assay.
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3.2 Colony Formation Assays
As shown in Figure 3, the therapeutic effects of MCI-062 in the A549 and H358
lung cancer cell lines were determined using a colony formation assay, which evaluates
the proliferation and growth capacity of cancer cells. The H358 and A549 cells were
grown in normal growth medium with 10% fetal bovine serum supplemented Roswell
Park Memorial Institute (FBS RPMI)-1640 medium in a 12-well plate for 10 days. The
plate was incubated with stain (0.5% crystal violet) for one hour to visualize the living
cell colonies that had formed. Plates containing the stained colonies were photographed
through microscopy, and colony formation was measured using a custom macro written
for NIS-Elements image analysis software (Laboratory Imaging) by Dr. Joel F. Andrews,
Manager of the Bioimaging Core Facility for the USA College of Medicine and USA
Mitchell Cancer Institute. This macro can analyze whole-plate images of 6 or 12-well cell
culture plates and reports colony formation as the number of observed colonies as well as
area fraction of the whole well. Following is a brief description of the macro's algorithm:
after selecting 6 or 12 well plate formats and naming the wells if desired, the user was
prompted to place a circular region of interest (ROI) over the first well, allowing for the
automated placement of the remaining wells of the plate, and removal of non-well image
data from the analysis. Thresholding on the image is then performed to delineate colonies
from background, followed by object counting and area measurement for each well.
Measured values are then exported to a tab-separated text file or Excel spreadsheet.
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Figure 3. Tissue culture and colony formation assay. Cells were taken from liquid nitrogen storage,
thawed, and plated into 10 mL cell culture dishes in liquid 10% FBS RPMI-1640 medium. Once the
cells reached confluence every 3-4 days, the cells would be passaged and split into new cell culture
dishes with new medium. To begin a colony formation assay, cells would be plated into a 12-well plate
and be allowed to grow for ten days. After ten days, the plates were photographed under microscopy,
and the digital images were analyzed in NIS-Elements.
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CHAPTER IV
RESULTS

4.1 Colony Formation in A Serial Dilution of A549 Cells
As shown in Figure 4, to test the inhibitory effects of the pan-RAS inhibitor
MCI-062, the best conditions and cell numbers for colony formation were determined
using a serial dilution of A549 cells (KRASG13D) starting from 1000 cells/well (4A). As
indicated in 4B and 4C, the best condition to test the therapeutic effect of drug treatment
in tumor cell colony formation was found to be between 63 and 125 cells, as these cell
concentrations resulted in colony growth that was neither too crowded nor too sparse.
Cell overcrowding can lead to an underestimation of colony number due to interference
with the software’s ability to identify individual colonies, as seen with colony number for
the 1000 cells/well concentration in 4C. 80 cells/well was the concentration of A549 cells
used in the subsequent colony formation assays.
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Figure 4. Colony formation assay with A549 lung cancer cells. (A). Cells were
cultured in a 12-well plate with a serial dilution starting with 1000 A549 cells per well.
Cells were incubated and monitored for 10 days. Colonies were stained with 0.5% crystal
violet dye so that the live colonies could be analyzed. The area fraction (B) and the
colony number (C) were calculated using data from NIS-Elements, and the graphs were
created using GraphPad Prism 7.
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4.2 Quantification of MCI-062 in Suppressing Cell Growth of A549 Cells
From the results in Figure 4, an 80-cell initial cell plating density was used to
determine the potency of MCI-062 to inhibit the growth of A549 cells. For the first
attempt, a concentration range of 0-500 nM MCI-062 was used (Figure 5). These results
indicated that the A549 lung cancer cells did not survive when the MCI-062
concentration exceeded 20 nM. However, given the relatively wide gaps between
experimental conditions, lower concentrations of MCI-062 were used in the next step to
determine a more precise concentration at which MCI-062 begins to show signs of cancer
cell inhibition.

0

0

0.8

0.8

4

4

20

20

100

100

500

500

MCI-062 (nM)

Figure 5. Inhibitory effects of MCI-062 on the growth of A549 lung
cancer cells. Colony formation was analyzed in MCI-062 at 0, 0.8, 4, 20,
100, 500 nM using a crystal violet dye.
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For the next experiment, the concentrations of MCI-062 used were 0, 1.5, 3.1,
6.13, 12.25 or 25 nM (Figure 6). The results demonstrated that MCI-062 concentration
that fully inhibited fully inhibited A549 cell growth was somewhere between 3.1 nM and
6.3 nM (6A). The half maximal effective concentration (EC50) of MCI-062 was
interpolated from an area fraction vs. MCI-062 concentration constructed in GraphPad
Prism, which was found to be 3.025 nM (6B). This value suggests that MCI-062 inhibits
50% of A549 cell (KRASG13D) growth at 3.025 nM.
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Figure 6. Pan-RAS inhibitor MCI-062 suppresses colony formation
of A549 lung cancer cells in a dose-dependent manner. (A). Colony
formation assay was performed in the presence of 80 cells of A549 in
the treatment with 0, 1.5, 3.1, 6.3, 12.5, or 25 nM of MCI-062 for 10
days. (B). The EC50 was calculated in GraphPad Prism.
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4.3 Colony Formation Assays with H358 Cells
To determine the inhibitory effects of the novel RAS inhibitor MCI-062 in
another type of KRAS mutant cells, the H358 (KRASG12C) lung cancer cell line was used
in similar experiments as A549 cells. As shown in Figure 7A, the optimal condition in
colony formation for H358 was 2,500 cells. The H358 cells responded similarly to the
A549 cells in the colony formation assay (Figures 7B and 7C). EC50 of MCI-062 for
H358 cells was determined using GraphPad Prism in the same manner as for the A549
cells and was found to be ~3.088 nM under their own optimal cell concentration.
The results from Figure 6 and Figure 7A indicated that novel small molecule
inhibitor MCI-062 could inhibit A549 (KRASG13D) cells and H358 (KRASG12C) cells with
similar potency. Furthermore, these results demonstrate that MCI-062 inhibits the growth
of lung cancer cells with both KRASG12C and KRASG13D mutations.
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Figure 7. Pan-RAS inhibitor MCI-062 suppresses colony formation of H358 lung cancer cells in a dose-dependent
manner. (A). Colony formation in a serial dilution of H358 cells. (B). Colony formation assay was performed in presence
of 2,500 cells of H358 in the treatment with 0, 1.5, 3.1, 6.3, 12.5, or 25 nM of MCI-062 for 10 days. (C). The EC50 was
calculated using area fraction in GraphPad Prism.
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CHAPTER V
DISCUSSION

The results of this project indicate that MCI-062 effectively inhibits the growth
and proliferation of H358 and A549 lung cancer cells, which supports the original
hypothesis. MCI-062’s suppression of both cell lines suggests that MCI-062 extends
KRAS inhibition from solely KRASG12C to at least both KRASG12C and KRASG13D, going
beyond the capabilities of AMG 510 and other KRAS inhibitors being studied (20). As
stated in the Introduction, the exact mechanisms of MCI-062 are still being studied and
outside of the scope of this project. However, the research data suggest the potential for
MCI-062 to have a novel but not-yet defined mechanism of inhibition distinct from other
known inhibitors that are limited to KRASG12C mutations, which encourages advanced
preclinical investigation in animal models to support clinical evaluation.
Drugs developed for RAS or KRAS inhibition, such as MCI-062 and AMG 510,
will potentially provide a cure to a specific population of lung cancer patients. As with
most anti-cancer treatments, RAS inhibitors have the potential to lose efficacy due to
drug resistance in patients. One potential solution to overcome such drug resistance is the
development and use of combination therapies with inhibitors downstream of RAS to the
RAF-MEK-ERK and PI3K/AKT/mTOR pathways and immunotherapies (6, 7, 17, 20,
25, 32). Many potential combination therapies have been employed in cancer patients,
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especially in lung cancer and colon cancer (21, 32). Studies have shown that MEK
inhibitors (MEKi) have a synergistic effect on suppressing tumor growth in combination
with the KRAS inhibitor AMG 510 (20). The therapeutic efficacy of MCI-062 treatment
in combination with immunotherapies, including anti-PD-1 and anti-PD-L1, is also
promising, as previous results have indicated that the combination of KRAS inhibitor
AMG 510 with anti-PD-1 has a significantly higher survival rate than both single
treatment groups in a preclinical model (20). Other studies have demonstrated that KRAS
inhibitor AMG 510 suppresses tumor growth in a dose-dependent manner, which is
important for implementation in clinical use (20).
The continuation of this project might contribute to the development of a novel
targeted therapy for KRAS-driven cancer patients, a population in desperate need of
effective treatment options, and reach the goal of personalized medicine in these patients.
Potential future directions include comparing the therapeutic efficacies of MCI-062 and
AMG 510 in more lung cancer cell lines, studying the duration of the drug response and
its interaction with approved EGFR, RAF, and MEK kinase inhibitors, and testing MCI062’s therapeutic efficacy in combination with immunotherapies. MCI-062 may also
serve as a useful probe in studying KRAS inhibition in cancer treatment by providing
powerful information for developing optimal targeted therapies for cancer patients.
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CHAPTER VI
CONCLUSIONS

The results of this project demonstrate that MCI-062 inhibits the growth of lung
cancer A549 cells with KRASG13D mutation and H358 cells with KRASG12C mutation. This
study suggests that MCI-062 might exhibit therapeutic action against KRAS-mutant lung
cancers even when they express different mutant isoforms, which supports the notion that
MCI-062 acts as a pan-RAS inhibitor. This unique property may help advance the field of
targeted treatment of patients with lung cancer involving KRAS mutations regardless of
whether their specific mutation is KRASG13D, KRASG12C, or one of the other many
isoforms that have been described in lung cancer and other cancer types..
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